{"organizations": [], "uuid": "0e4eccce865ae0188fa22f46b4b6e743c7b0cdc1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180416.html", "section_title": "Archive News &amp; Video for Monday, 16 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-astrazeneca-updates-on-overall-sur/brief-astrazeneca-updates-on-overall-survival-data-for-lynparza-presented-at-aacr-idUSFWN1RT03Q", "country": "US", "domain_rank": 408, "title": "BRIEF-AstraZeneca Updates On Overall Survival Data For Lynparza Presented At AACR", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.496, "site_type": "news", "published": "2018-04-16T14:17:00.000+03:00", "replies_count": 0, "uuid": "0e4eccce865ae0188fa22f46b4b6e743c7b0cdc1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-astrazeneca-updates-on-overall-sur/brief-astrazeneca-updates-on-overall-survival-data-for-lynparza-presented-at-aacr-idUSFWN1RT03Q", "ord_in_thread": 0, "title": "BRIEF-AstraZeneca Updates On Overall Survival Data For Lynparza Presented At AACR", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "aacr", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "brief-astrazeneca updates on overall survival data for lynparza", "sentiment": "negative"}, {"name": "lynparza", "sentiment": "negative"}, {"name": "astrazeneca plc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 16 (Reuters) - AstraZeneca PLC:\n* UPDATED OVERALL SURVIVAL DATA FOR LYNPARZA IN BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER PRESENTED AT AACR\n* LYNPARZA TRIAL MET ITS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL\n* RESULTS AT AACR INCLUDE UPDATED FINDINGS FROM SECONDARY ENDPOINT OF OVERALL SURVIVAL Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-16T14:17:00.000+03:00", "crawled": "2018-04-17T12:09:51.062+03:00", "highlightTitle": ""}